Intra-arterial transplantation of HLA-matched donor mesoangioblasts in Duchenne muscular dystrophy

Giulio Cossu, Stefano C. Previtali, Sara Napolitano, Maria Pia Cicalese, Francesco Saverio Tedesco, Francesca Nicastro, Maddalena Noviello, Urmas Roostalu, Maria Grazia Natali Sora, Marina Scarlato, Maurizio De Pellegrin, Claudia Godi, Serena Giuliani, Francesca Ciotti, Rossana Tonlorenzi, Isabella Lorenzetti, Cristina Rivellini, Sara Benedetti, Roberto Gatti, Sarah Marktel & 13 others Benedetta Mazzi, Andrea Tettamanti, Martina Ragazzi, Maria Adele Imro, Giuseppina Marano, Alessandro Ambrosi, Rossana Fiori, Maria Pia Sormani, Chiara Bonini, Massimo Venturini, Letterio S. Politi, Yvan Torrente, Fabio Ciceri

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Intra-arterial transplantation of mesoangioblasts proved safe and partially efficacious in preclinical models of muscular dystrophy. We now report the first-in-human, exploratory, non-randomized open-label phase I-IIa clinical trial of intra-arterial HLA-matched donor cell transplantation in 5 Duchenne patients. We administered escalating doses of donor-derived mesoangioblasts in limb arteries under immunosuppressive therapy (tacrolimus). Four consecutive infusions were performed at 2-month intervals, preceded and followed by clinical, laboratory, and muscular MRI analyses. Two months after the last infusion, a muscle biopsy was performed. Safety was the primary endpoint. The study was relatively safe: One patient developed a thalamic stroke with no clinical consequences and whose correlation with mesoangioblast infusion remained unclear. MRI documented the progression of the disease in 4/5 patients. Functional measures were transiently stabilized in 2/3 ambulant patients, but no functional improvements were observed. Low level of donor DNA was detected in muscle biopsies of 4/5 patients and donor-derived dystrophin in 1. Intra-arterial transplantation of donor mesoangioblasts in human proved to be feasible and relatively safe. Future implementation of the protocol, together with a younger age of patients, will be needed to approach efficacy. Synopsis: This study reports a safe, first-in-human mesoangioblast cell therapy to treat Duchenne muscular dystrophy (DMD) in 5 young patients, using a successful preclinical strategy, as an exploratory non-randomized open-label phase I-IIa clinical trial of intra-arterial HLA-matched donor cell transplantation. Five patients affected by DMD were treated by intra-arterial infusions of escalating doses of HLA-matched donor mesoangioblasts. The trial was overall safe but showed minimal, if any, efficacy. Data analysis suggested to treat patients at an earlier stage of the disease, optimize in in vitro models each single step of the transplantation protocol, and use genetically corrected, autologous mesoangioblasts in a future trial. This study reports a safe, first-in-human mesoangioblast cell therapy to treat Duchenne muscular dystrophy (DMD) in 5 young patients, using a successful preclinical strategy, as an exploratory non-randomized open-label phase I-IIa clinical trial of intra-arterial HLA-matched donor cell transplantation.

Original languageEnglish
Pages (from-to)1513-1528
Number of pages16
JournalEMBO Molecular Medicine
Volume7
Issue number12
DOIs
Publication statusPublished - Dec 1 2015

Fingerprint

Duchenne Muscular Dystrophy
Transplantation
Tissue Donors
Clinical Trials, Phase I
Cell Transplantation
Cell- and Tissue-Based Therapy
Biopsy
Intra Arterial Infusions
Muscles
Dystrophin
Muscular Dystrophies
Tacrolimus
Immunosuppressive Agents
Disease Progression
Extremities
Arteries
Stroke
Safety

Keywords

  • Cell therapy
  • Duchenne
  • Dystrophin
  • Mesoangioblast
  • MRI

ASJC Scopus subject areas

  • Molecular Medicine

Cite this

Intra-arterial transplantation of HLA-matched donor mesoangioblasts in Duchenne muscular dystrophy. / Cossu, Giulio; Previtali, Stefano C.; Napolitano, Sara; Cicalese, Maria Pia; Tedesco, Francesco Saverio; Nicastro, Francesca; Noviello, Maddalena; Roostalu, Urmas; Natali Sora, Maria Grazia; Scarlato, Marina; De Pellegrin, Maurizio; Godi, Claudia; Giuliani, Serena; Ciotti, Francesca; Tonlorenzi, Rossana; Lorenzetti, Isabella; Rivellini, Cristina; Benedetti, Sara; Gatti, Roberto; Marktel, Sarah; Mazzi, Benedetta; Tettamanti, Andrea; Ragazzi, Martina; Imro, Maria Adele; Marano, Giuseppina; Ambrosi, Alessandro; Fiori, Rossana; Sormani, Maria Pia; Bonini, Chiara; Venturini, Massimo; Politi, Letterio S.; Torrente, Yvan; Ciceri, Fabio.

In: EMBO Molecular Medicine, Vol. 7, No. 12, 01.12.2015, p. 1513-1528.

Research output: Contribution to journalArticle

Cossu, G, Previtali, SC, Napolitano, S, Cicalese, MP, Tedesco, FS, Nicastro, F, Noviello, M, Roostalu, U, Natali Sora, MG, Scarlato, M, De Pellegrin, M, Godi, C, Giuliani, S, Ciotti, F, Tonlorenzi, R, Lorenzetti, I, Rivellini, C, Benedetti, S, Gatti, R, Marktel, S, Mazzi, B, Tettamanti, A, Ragazzi, M, Imro, MA, Marano, G, Ambrosi, A, Fiori, R, Sormani, MP, Bonini, C, Venturini, M, Politi, LS, Torrente, Y & Ciceri, F 2015, 'Intra-arterial transplantation of HLA-matched donor mesoangioblasts in Duchenne muscular dystrophy', EMBO Molecular Medicine, vol. 7, no. 12, pp. 1513-1528. https://doi.org/10.15252/emmm.201505636
Cossu, Giulio ; Previtali, Stefano C. ; Napolitano, Sara ; Cicalese, Maria Pia ; Tedesco, Francesco Saverio ; Nicastro, Francesca ; Noviello, Maddalena ; Roostalu, Urmas ; Natali Sora, Maria Grazia ; Scarlato, Marina ; De Pellegrin, Maurizio ; Godi, Claudia ; Giuliani, Serena ; Ciotti, Francesca ; Tonlorenzi, Rossana ; Lorenzetti, Isabella ; Rivellini, Cristina ; Benedetti, Sara ; Gatti, Roberto ; Marktel, Sarah ; Mazzi, Benedetta ; Tettamanti, Andrea ; Ragazzi, Martina ; Imro, Maria Adele ; Marano, Giuseppina ; Ambrosi, Alessandro ; Fiori, Rossana ; Sormani, Maria Pia ; Bonini, Chiara ; Venturini, Massimo ; Politi, Letterio S. ; Torrente, Yvan ; Ciceri, Fabio. / Intra-arterial transplantation of HLA-matched donor mesoangioblasts in Duchenne muscular dystrophy. In: EMBO Molecular Medicine. 2015 ; Vol. 7, No. 12. pp. 1513-1528.
@article{f75f99b695944835a53920a972a0b984,
title = "Intra-arterial transplantation of HLA-matched donor mesoangioblasts in Duchenne muscular dystrophy",
abstract = "Intra-arterial transplantation of mesoangioblasts proved safe and partially efficacious in preclinical models of muscular dystrophy. We now report the first-in-human, exploratory, non-randomized open-label phase I-IIa clinical trial of intra-arterial HLA-matched donor cell transplantation in 5 Duchenne patients. We administered escalating doses of donor-derived mesoangioblasts in limb arteries under immunosuppressive therapy (tacrolimus). Four consecutive infusions were performed at 2-month intervals, preceded and followed by clinical, laboratory, and muscular MRI analyses. Two months after the last infusion, a muscle biopsy was performed. Safety was the primary endpoint. The study was relatively safe: One patient developed a thalamic stroke with no clinical consequences and whose correlation with mesoangioblast infusion remained unclear. MRI documented the progression of the disease in 4/5 patients. Functional measures were transiently stabilized in 2/3 ambulant patients, but no functional improvements were observed. Low level of donor DNA was detected in muscle biopsies of 4/5 patients and donor-derived dystrophin in 1. Intra-arterial transplantation of donor mesoangioblasts in human proved to be feasible and relatively safe. Future implementation of the protocol, together with a younger age of patients, will be needed to approach efficacy. Synopsis: This study reports a safe, first-in-human mesoangioblast cell therapy to treat Duchenne muscular dystrophy (DMD) in 5 young patients, using a successful preclinical strategy, as an exploratory non-randomized open-label phase I-IIa clinical trial of intra-arterial HLA-matched donor cell transplantation. Five patients affected by DMD were treated by intra-arterial infusions of escalating doses of HLA-matched donor mesoangioblasts. The trial was overall safe but showed minimal, if any, efficacy. Data analysis suggested to treat patients at an earlier stage of the disease, optimize in in vitro models each single step of the transplantation protocol, and use genetically corrected, autologous mesoangioblasts in a future trial. This study reports a safe, first-in-human mesoangioblast cell therapy to treat Duchenne muscular dystrophy (DMD) in 5 young patients, using a successful preclinical strategy, as an exploratory non-randomized open-label phase I-IIa clinical trial of intra-arterial HLA-matched donor cell transplantation.",
keywords = "Cell therapy, Duchenne, Dystrophin, Mesoangioblast, MRI",
author = "Giulio Cossu and Previtali, {Stefano C.} and Sara Napolitano and Cicalese, {Maria Pia} and Tedesco, {Francesco Saverio} and Francesca Nicastro and Maddalena Noviello and Urmas Roostalu and {Natali Sora}, {Maria Grazia} and Marina Scarlato and {De Pellegrin}, Maurizio and Claudia Godi and Serena Giuliani and Francesca Ciotti and Rossana Tonlorenzi and Isabella Lorenzetti and Cristina Rivellini and Sara Benedetti and Roberto Gatti and Sarah Marktel and Benedetta Mazzi and Andrea Tettamanti and Martina Ragazzi and Imro, {Maria Adele} and Giuseppina Marano and Alessandro Ambrosi and Rossana Fiori and Sormani, {Maria Pia} and Chiara Bonini and Massimo Venturini and Politi, {Letterio S.} and Yvan Torrente and Fabio Ciceri",
year = "2015",
month = "12",
day = "1",
doi = "10.15252/emmm.201505636",
language = "English",
volume = "7",
pages = "1513--1528",
journal = "EMBO Molecular Medicine",
issn = "1757-4676",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Intra-arterial transplantation of HLA-matched donor mesoangioblasts in Duchenne muscular dystrophy

AU - Cossu, Giulio

AU - Previtali, Stefano C.

AU - Napolitano, Sara

AU - Cicalese, Maria Pia

AU - Tedesco, Francesco Saverio

AU - Nicastro, Francesca

AU - Noviello, Maddalena

AU - Roostalu, Urmas

AU - Natali Sora, Maria Grazia

AU - Scarlato, Marina

AU - De Pellegrin, Maurizio

AU - Godi, Claudia

AU - Giuliani, Serena

AU - Ciotti, Francesca

AU - Tonlorenzi, Rossana

AU - Lorenzetti, Isabella

AU - Rivellini, Cristina

AU - Benedetti, Sara

AU - Gatti, Roberto

AU - Marktel, Sarah

AU - Mazzi, Benedetta

AU - Tettamanti, Andrea

AU - Ragazzi, Martina

AU - Imro, Maria Adele

AU - Marano, Giuseppina

AU - Ambrosi, Alessandro

AU - Fiori, Rossana

AU - Sormani, Maria Pia

AU - Bonini, Chiara

AU - Venturini, Massimo

AU - Politi, Letterio S.

AU - Torrente, Yvan

AU - Ciceri, Fabio

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Intra-arterial transplantation of mesoangioblasts proved safe and partially efficacious in preclinical models of muscular dystrophy. We now report the first-in-human, exploratory, non-randomized open-label phase I-IIa clinical trial of intra-arterial HLA-matched donor cell transplantation in 5 Duchenne patients. We administered escalating doses of donor-derived mesoangioblasts in limb arteries under immunosuppressive therapy (tacrolimus). Four consecutive infusions were performed at 2-month intervals, preceded and followed by clinical, laboratory, and muscular MRI analyses. Two months after the last infusion, a muscle biopsy was performed. Safety was the primary endpoint. The study was relatively safe: One patient developed a thalamic stroke with no clinical consequences and whose correlation with mesoangioblast infusion remained unclear. MRI documented the progression of the disease in 4/5 patients. Functional measures were transiently stabilized in 2/3 ambulant patients, but no functional improvements were observed. Low level of donor DNA was detected in muscle biopsies of 4/5 patients and donor-derived dystrophin in 1. Intra-arterial transplantation of donor mesoangioblasts in human proved to be feasible and relatively safe. Future implementation of the protocol, together with a younger age of patients, will be needed to approach efficacy. Synopsis: This study reports a safe, first-in-human mesoangioblast cell therapy to treat Duchenne muscular dystrophy (DMD) in 5 young patients, using a successful preclinical strategy, as an exploratory non-randomized open-label phase I-IIa clinical trial of intra-arterial HLA-matched donor cell transplantation. Five patients affected by DMD were treated by intra-arterial infusions of escalating doses of HLA-matched donor mesoangioblasts. The trial was overall safe but showed minimal, if any, efficacy. Data analysis suggested to treat patients at an earlier stage of the disease, optimize in in vitro models each single step of the transplantation protocol, and use genetically corrected, autologous mesoangioblasts in a future trial. This study reports a safe, first-in-human mesoangioblast cell therapy to treat Duchenne muscular dystrophy (DMD) in 5 young patients, using a successful preclinical strategy, as an exploratory non-randomized open-label phase I-IIa clinical trial of intra-arterial HLA-matched donor cell transplantation.

AB - Intra-arterial transplantation of mesoangioblasts proved safe and partially efficacious in preclinical models of muscular dystrophy. We now report the first-in-human, exploratory, non-randomized open-label phase I-IIa clinical trial of intra-arterial HLA-matched donor cell transplantation in 5 Duchenne patients. We administered escalating doses of donor-derived mesoangioblasts in limb arteries under immunosuppressive therapy (tacrolimus). Four consecutive infusions were performed at 2-month intervals, preceded and followed by clinical, laboratory, and muscular MRI analyses. Two months after the last infusion, a muscle biopsy was performed. Safety was the primary endpoint. The study was relatively safe: One patient developed a thalamic stroke with no clinical consequences and whose correlation with mesoangioblast infusion remained unclear. MRI documented the progression of the disease in 4/5 patients. Functional measures were transiently stabilized in 2/3 ambulant patients, but no functional improvements were observed. Low level of donor DNA was detected in muscle biopsies of 4/5 patients and donor-derived dystrophin in 1. Intra-arterial transplantation of donor mesoangioblasts in human proved to be feasible and relatively safe. Future implementation of the protocol, together with a younger age of patients, will be needed to approach efficacy. Synopsis: This study reports a safe, first-in-human mesoangioblast cell therapy to treat Duchenne muscular dystrophy (DMD) in 5 young patients, using a successful preclinical strategy, as an exploratory non-randomized open-label phase I-IIa clinical trial of intra-arterial HLA-matched donor cell transplantation. Five patients affected by DMD were treated by intra-arterial infusions of escalating doses of HLA-matched donor mesoangioblasts. The trial was overall safe but showed minimal, if any, efficacy. Data analysis suggested to treat patients at an earlier stage of the disease, optimize in in vitro models each single step of the transplantation protocol, and use genetically corrected, autologous mesoangioblasts in a future trial. This study reports a safe, first-in-human mesoangioblast cell therapy to treat Duchenne muscular dystrophy (DMD) in 5 young patients, using a successful preclinical strategy, as an exploratory non-randomized open-label phase I-IIa clinical trial of intra-arterial HLA-matched donor cell transplantation.

KW - Cell therapy

KW - Duchenne

KW - Dystrophin

KW - Mesoangioblast

KW - MRI

UR - http://www.scopus.com/inward/record.url?scp=84954401426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954401426&partnerID=8YFLogxK

U2 - 10.15252/emmm.201505636

DO - 10.15252/emmm.201505636

M3 - Article

VL - 7

SP - 1513

EP - 1528

JO - EMBO Molecular Medicine

JF - EMBO Molecular Medicine

SN - 1757-4676

IS - 12

ER -